Iqvia Holdings Inc (NYSE:IQV) Receives $166.46 Average Price Target from Brokerages

Iqvia Holdings Inc (NYSE:IQV) has earned a consensus recommendation of “Buy” from the twenty ratings firms that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $166.46.

Several equities analysts recently weighed in on IQV shares. Wolfe Research upgraded Iqvia from a “peer perform” rating to an “outperform” rating in a research report on Thursday, November 14th. ValuEngine downgraded Iqvia from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd.

Institutional investors have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. raised its holdings in shares of Iqvia by 2.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 5,322 shares of the medical research company’s stock worth $856,000 after purchasing an additional 102 shares during the period. Parallel Advisors LLC grew its stake in shares of Iqvia by 27.0% in the second quarter. Parallel Advisors LLC now owns 512 shares of the medical research company’s stock valued at $82,000 after buying an additional 109 shares in the last quarter. Montag & Caldwell LLC grew its stake in shares of Iqvia by 3.3% in the third quarter. Montag & Caldwell LLC now owns 2,840 shares of the medical research company’s stock valued at $424,000 after buying an additional 90 shares in the last quarter. D.A. Davidson & CO. grew its stake in shares of Iqvia by 10.0% in the third quarter. D.A. Davidson & CO. now owns 12,102 shares of the medical research company’s stock valued at $1,808,000 after buying an additional 1,102 shares in the last quarter. Finally, APG Asset Management N.V. grew its stake in shares of Iqvia by 120.8% in the second quarter. APG Asset Management N.V. now owns 34,000 shares of the medical research company’s stock valued at $4,804,000 after buying an additional 18,600 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

NYSE IQV opened at $143.84 on Monday. The business’s 50-day moving average price is $144.73 and its 200 day moving average price is $149.71. Iqvia has a twelve month low of $104.90 and a twelve month high of $164.13. The company has a market capitalization of $28.41 billion, a PE ratio of 28.09, a price-to-earnings-growth ratio of 1.79 and a beta of 0.87. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 1.85.

Iqvia (NYSE:IQV) last released its earnings results on Wednesday, October 30th. The medical research company reported $1.60 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.57 by $0.03. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.76 billion. During the same period in the prior year, the business posted $1.42 earnings per share. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. Equities analysts predict that Iqvia will post 5.9 EPS for the current year.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading: What is the Beige Book?

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.